Fibralign has recently closed a syndicate funding round coordinated by investment and networking platform AngelMD to support its Nanoweave 3D scaffolding tech and medical devices using the technology.
The Union City, Calif.-based company’s first product is the BioBridge collagen matrix, which is an implantable, biocompatible and biodegradable surgical mesh with 510(k) clearance for use in surgery to “reinforce and repair soft tissue where weakness and deficiencies exist,” the company said.
Fibralign is currently exploring use of the device to treat patients who suffer from secondary lymphedema.
“Secondary lymphedema, which occurs when the lymphatic system is disrupted and unable to transport interstitial fluid, most commonly occurs as a result of cancer treatments in western countries. Conventional therapies are costly, marginally successful, and treat symptoms only. To an area in great need of a new approach, the team at Fibralign has introduced a novel BioBridge Collagen Matrix which acts as a 3D scaffolding to promote the growth of new lymphatic vessels and dramatically improve the quality of life for millions of people,” syndicate leader Dr. Orrin Ailloni-Charas said in a press release.
The company is also exploring follow-on opportunities with the BioBridge, including treatments for ischemia, cell and drug delivery and gene therapy, according to a press release.
“We are honored to have AngelMD join us and support our advancement of a much-needed treatment for lymphedema. AngelMD brings much more than capital with its investment to Fibralign. Engaging their network of physicians has been invaluable in providing feedback for our product pipeline and clinical direction,” Fibralign CEO Greg King said in a prepared statement.
The amount of funding raised in the round was not disclosed.
Last September, Stanford University began enrollment in an investigator-led clinical study of the BioBridge collagen matrix for treating secondary lymphedema.